Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (261-270 of 343) with videos related to

Pageof 35
Sort By:
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Rheumatology and Therapy|May 5, 2025
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.
Seminars in Arthritis and Rheumatism|August 16, 2021
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PFYing-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, et al.
RMD Open|August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studiesLaura C Coates, Ricardo Blanco, Frank Behrens, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Seminars in Arthritis and Rheumatism|September 14, 2020
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic reviewYing-Ying Leung, Richard Holland, Ashish J Mathew, et al.
Pageof 35

Showing results (261-270 of 343) with videos related to

Sort By:
Pageof 35
Rheumatology Advances in Practice|November 15, 2021
Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort studyMarie Skougaard, Tanja S Jørgensen, Mia J Jensen, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Rheumatology and Therapy|May 5, 2025
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
Nature Medicine|October 6, 2025
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trialIain B McInnes, Laura C Coates, Philip J Mease, et al.
Seminars in Arthritis and Rheumatism|August 16, 2021
OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PFYing-Ying Leung, Ana-Maria Orbai, Pil Hojgaard, et al.
RMD Open|August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studiesLaura C Coates, Ricardo Blanco, Frank Behrens, et al.
Rheumatology and Therapy|August 31, 2024
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Rheumatology and Therapy|May 10, 2025
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 StudiesPhilip J Mease, Joseph F Merola, Yoshiya Tanaka, et al.
Seminars in Arthritis and Rheumatism|September 14, 2020
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic reviewYing-Ying Leung, Richard Holland, Ashish J Mathew, et al.
Pageof 35